Alimta Lung Cancer
In a head-to head trial comparing Alimta (pemetrexed, Eli Lilly and Company, Indianapolis, IN) with Taxotere (docetaxel, Aventis Pharmaceuticals, Inc., Bridgewater, NJ), Alimta showed a similar survival benefit with significantly fewer side effects in subjects with recurrent non-small cell lung cancer. (Trials in progress: Phase 3).(Brief Article) In a head-to head trial comparing Alimta (pemetrexed, Eli Lilly and Company, Indianapolis, IN) with Taxotere (docetaxel, Aventis Pharmaceuticals, Inc., Bridgewater, NJ), Alimta showed a similiar survival benefit with significantly fewer side effects in subjects with recurrent non-small cell lung cancer. Results of this Phase 3 global study enrolled 571 subjects previously treated with chemotherapy. Of these subjects, 283 were randomized to receive docetaxel ...
|
